Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript

Bristol Myers Squibb reported Q3 revenue of $13.1 billion, up 7% year over year, as growth-portfolio revenue rose 12% to $7.7 billion; non-GAAP EPS was $1.35, including a $0.58 per-share impact from acquired R&D charges and licensing income. The company raised 2026 revenue guidance to $49.75 billion–$50.25 billion and set non-GAAP EPS guidance at $6.35–$6.55. Management cited pipeline progress and eight growth medicines each annualizing above $1 billion, while flagging a projected $1.5 billion–$2 billion Eliquis revenue step-down in 2027 from European loss of exclusivity and a paused Zolacel program following one septic-pneumonia death among 190 Phase 1 patients.

Analysis

The key underwriting question is whether BMY’s newer franchises can absorb the 2027 Eliquis European LOE before the market starts discounting the revenue gap. The broad growth portfolio reduces dependence on any single launch, but reported growth is not equivalent to durable earnings growth: Opdivo-to-Qvantig conversion can defend the franchise and improve treatment convenience while partly shifting, rather than adding, existing sales. Track total franchise revenue and economics, not Qvantig uptake alone.

Near term, guidance momentum is supportive, but headline EPS is clouded by acquired IPR&D and licensing items; the 68.4% gross margin also includes product mix and a one-time termination expense, so neither should be extrapolated without a cleaner underlying margin bridge. Camzyos and Cobenfy inventory effects make prescription trends more informative than quarterly sales alone. The more consequential 1–3 month catalysts are Milvexian secondary-stroke and Sotyktu lupus results; disappointment would weaken the pipeline-offset narrative. Cobenfy’s adoption still depends on prescribers titrating patients to effective doses and managing tolerability—prescriber growth alone is not proof of commercial conversion.

For 6–18 months, the Eliquis step-down is a tangible headwind against which pipeline launches and cost savings must be measured. RAISE 101 and cell-therapy programs add option value, not yet a substitute for established revenue; the fatal zola-cel event and clinical pause preserve safety and restart risk. Bayer’s cited small-cell data also raise the bar for BMY’s competing oncology combinations, though not enough here to infer a direct near-term revenue impact. The contrarian risk is that investors capitalize pipeline breadth before evidence of launch scale; verify valuation and post-earnings price action before adding exposure.

Key Decisions for Investors

• Consider a modest, staged long BMY versus a diversified pharma benchmark only on post-results weakness, rather than chasing a positive reaction. Add only if growth-portfolio sales and underlying margins hold up; this is a carry-and-execution thesis, not a claim that pipeline optionality offsets LOE dollar-for-dollar.
• Treat Milvexian secondary-stroke and Sotyktu lupus results as binary catalysts: avoid increasing exposure immediately ahead of the readouts unless sized for trial risk. A negative efficacy or safety signal would challenge the pipeline-offset case; positive results still require commercial and regulatory validation.
• Monitor Eliquis European sales, the company’s 2027 revenue bridge, and growth-portfolio contribution. Reassess or exit the long thesis if legacy decline exceeds the guided 3–5% range without offsetting growth, or if growth-portfolio momentum materially decelerates.
• Do not underwrite Qvantig conversion as incremental growth by itself. Verify total Opdivo-plus-Qvantig revenue and margin trends; a rising Qvantig mix alongside continued franchise contraction would falsify the cannibalization-protection thesis.